# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **SCHEDULE 13G**

<b>Under the Securities Exchange Act of 1934</b>				
(Amendment No. 1)*				
PIERIS PHARMACEUTICALS, INC.				
(Name of Issuer)				
Common Stock				
(Title of Class of Securities)				
720795103				
(CUSIP Number)				
December 31, 2016				
(Date of Event which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
□ Rule 13d-1(b)				
□ Rule 13d-1(c)				
⊠ Rule 13d-1(d)				
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.				
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i> ).				
Page 1 of 5				

- 1	1 3	
	•	

CUSIP No. 720795103

1.	NAMES OF REPORTING PERSONS				
	Novo	Nordisk A/	S		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  (a) □				
				(b) 🗆	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	The Kingdom of Denmark				
			SOLE VOTING POWER		
NUMBER OF		5.	0		
		7	SHARED VOTING POWER		
SHARES BENEFICIAI	<b>6.</b> LLY		0		
OWNED BY EACH REPORTING PERSON WITH		7	SOLE DISPOSITIVE POWER		
		7.	0		
			SHARED DISPOSITIVE POWER		
		8.	0		
9.	AGG	REGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
- 44					
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	0%				
12.	TYPE OF REPORTING PERSON*				
	СО				

Page 2 of 5

Item 1(a). Name of Issuer:				
Pieris Pharmaceuticals, Inc.				
Item 1(b). Address of Issuer's Principal Executive Offices:				
Lise-Meitner-Strasse 30				
85354 Freising-Weihenstephan				
Germany				
Item 2(a). Name of Person Filing:				
Novo Nordisk A/S				
Item 2(b). Address of Principal Business Office or, if None, Residence:				
Novo Allé				
DK – 2880, Bagsvaerd				
Denmark				
Item 2(c). Citizenship:				
The Kingdom of Demark				
Item 2(d). Title of Class of Securities:				
Common Stock				
Item 2(e). CUSIP Number:				
720795103				
Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:				
(a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);				
(b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);				
(c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);				
(d) $\square$ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);				
(e) $\square$ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);				
(f) $\square$ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);				
(g) $\square$ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);				
(h) $\square$ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);				
(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);				
(j) $\square$ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);				
(k) $\square$ Group, in accordance with §240.13d-1(b)(1)(ii)(K).				

### Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: See item 5 of cover page.
  - (ii) Shared power to vote or to direct the vote: See item 6 of cover page.
  - (iii) Sole power to dispose or to direct the disposition of: See item 7 of cover page.
  - (iv) Shared power to dispose or to direct the disposition of: See item 8 of cover page.

### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

## Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

### Item 8. Identification and Classification of Members of the Group.

Not applicable.

### Item 9. Notice of Dissolution of Group.

Not applicable.

### Item 10. Certifications.

Not applicable.

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify complete and correct.	that the information set forth in this statement is true,
	January 25, 2017
	(Date)
	/s/ Jesper Brandgaard
	(Signature)
	Jesper Brandgaard, Chief Financial Officer
	(Name/Title)
Page 5 of 5	